Works matching IS 01676997 AND DT 2006 AND VI 24 AND IP 2

Results: 8

Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience.

Published in:

Investigational New Drugs, 2006, v. 24, n. 2, p. 99, doi. 10.1007/s10637-006-5932-7

By:

Pierpaolo Correale;
Maria Cusi;
Lucia Micheli;
Cristina Nencini;
Maria del Vecchio;
Francesco Torino;
Angelo Aquino;
Enzo Bonmassar;
Guido Francini;
Giorgio Giorgi

Publication type:

Article

A Phase I Safety And Dose Escalation Trial Of Docetaxel CombinedWith GEM®231, A Second Generation Antisense OligonucleotideTargeting Protein Kinase A R1α In Patients With Advanced SolidCancers.

Published in:

Investigational New Drugs, 2006, v. 24, n. 2, p. 125, doi. 10.1007/s10637-006-2378-x

By:

Sanjay Goel;
Kavita Desai;
Manuel Macapinlac;
Scott Wadler;
Gary Goldberg;
Abbie Fields;
Mark Einstein;
Fabio Volterra;
Benny Wong;
Russell Martin;
Sridhar Mani

Publication type:

Article

Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies.

Published in:

Investigational New Drugs, 2006, v. 24, n. 2, p. 117, doi. 10.1007/s10637-006-2032-7

By:

Cheryl Cho;
George Fisher;
Joanne Halsey;
Branimir Sikic

Publication type:

Article

Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial.

Published in:

Investigational New Drugs, 2006, v. 24, n. 2, p. 151, doi. 10.1007/s10637-006-5937-2

By:

Toshiyuki Sawa;
Takashi Yana;
Minoru Takada;
Takahiko Sugiura;
Shinzoh Kudoh;
Tadashi Kamei;
Takeshi Isobe;
Hidehiko Yamamoto;
Soichiro Yokota;
Nobuyuki Katakami;
Yuji Tohda;
Akira Kawakami;
Yoichi Nakanishi;
Yutaka Ariyoshi

Publication type:

Article

Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study.

Published in:

Investigational New Drugs, 2006, v. 24, n. 2, p. 159, doi. 10.1007/s10637-006-5938-1

By:

Eric Winquist;
Jennifer Knox;
Jean-Pierre Ayoub;
Lori Wood;
Nancy Wainman;
Gregory Reid;
Laura Pearce;
Ajit Shah;
Elizabeth Eisenhauer

Publication type:

Article

Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma.

Published in:

Investigational New Drugs, 2006, v. 24, n. 2, p. 135, doi. 10.1007/s10637-006-5934-5

By:

Elisabeth Heath;
Barbara Burtness;
Lawrence Kleinberg;
Ronald Salem;
Stephen Yang;
Richard Heitmiller;
Marcia Canto;
Jonathan Knisely;
Mark Topazian;
Elizabeth Montgomery;
Nancy Tsottles;
Yazdi Pithavala;
Bridget Rohmiller;
Mary Collier;
Arlene Forastiere

Publication type:

Article

A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.

Published in:

Investigational New Drugs, 2006, v. 24, n. 2, p. 141, doi. 10.1007/s10637-006-5935-4

By:

Amy Peterson;
Helena Harlin;
Theodore Karrison;
Nicholas Vogelzang;
James Knost;
John Kugler;
Eric Lester;
Everett Vokes;
Thomas Gajewski;
Walter Stadler

Publication type:

Article

Novel in vitro model barriers for evaluation of the permeability of antitumor compounds, thioxanthones.

Published in:

Investigational New Drugs, 2006, v. 24, n. 2, p. 111

By:

Venugopal Marasanapalle;
Xiaoling Li;
Lisa Polin;
Bhaskara Jasti

Publication type:

Article